ClinicalTrials.gg
Sign In
DrugBiologicalRead study by study

Pembrolizumab clinical trials

Also written Keytruda, MK-3475, SCH 900475 and Lambrolizumab.

Includes 8 studies of Pembrolizumab, berahyaluronidase alfa drug combination.

studies test it
1,134
open now
281
in phase 3
153
first study started
2010
Related medicines add 8 studies

Counted the way a researcher would: Pembrolizumab with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.

This browser remembers your choice.

ClinicalTrials.gov finds 3,007 studies for pembrolizumab. How that becomes 1,134 here

Every study that search finds has been read, apart from the 18 newest, to see whether and how it gives pembrolizumab. ClinicalTrials.gov counts as of Nov 14, 2026. How drug pages count

  1. 3,007Found by its intervention search · See all 3,007 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 2,663 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. −34
    Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
  3. −3New since the last reading, not read yet
  4. +7Give it under a name that search misses: a biosimilar’s code or a misspelling
  5. 2,977Give pembrolizumab to participants
  6. −171Observe patients on it, or give it outside a trial
  7. −13Use it as a tool: an imaging tracer or a test of drug response
  8. −114Compare another treatment with it
  9. −1,545Give it beside what is tested
  10. 1,134Test it: the count on this site

Get an email when these change. Save the pembrolizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States
4 Sept 2014 · KEYTRUDA · BLA 125514 (FDA, Drugs@FDA)
European Union
17 Jul 2015 · Keytruda · EMEA/H/C/003820 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Pembrolizumab
864
Pembrolizumab Injection [Keytruda]
13
Pembrolizumab Injection
11
Pembrolizumab 200 mg
8
Pembrolizumab (MK-3475)
6

Brand

Keytruda
548

Development codes

MK-3475
365
SCH 900475
141
EVER4010001
1

Other names

Lambrolizumab
126

In one entry with another drug

Given together, or one or the other

pembrolizumab and lenvatinib
4
Pembrolizumab, paclitaxel
2
Pembrolizumab plus Lenvatinib
2
Nivolumab, Pembrolizumab
2
Pembrolizumab + Lenvatinib
2
ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab
2
Other ICIs
2

Biosimilars

QL2107
3
SB27
2
BAT3306
2
BCD-201
2
RPH-075
2
GME751
2

Studies by the year they started

1,130 studies that test it; most in 2017 (139); 4 more planned to start later

Studies that test pembrolizumab, by start year
YearStudies
20102
20111
20121
20138
201423
201573
2016113
2017139
2018114
201987
2020105
2021101
2022102
202373
202479
202557
202652

By phase

A phase 1/2 study counts in both.

Early Phase 1
25
Phase 1
199
Phase 2
828
Phase 3
153
Phase 4
11
No phase
12

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Carcinoma, Non-Small-Cell Lung
107
Melanoma
63
Breast Neoplasms
51
Squamous Cell Carcinoma of Head and Neck
51
Triple Negative Breast Neoplasms
41
Carcinoma, Renal Cell
36
Carcinoma, Hepatocellular
27
Stomach Neoplasms
25
Urinary Bladder Neoplasms
24
Colorectal Neoplasms
24
Hodgkin Disease
20
Head and Neck Neoplasms
19

Who runs them

Industry 192 · Other 942

Merck Sharp & Dohme LLC (144) · M.D. Anderson Cancer Center (47) · National Cancer Institute (NCI) (42) · Memorial Sloan Kettering Cancer Center (29) · Dana-Farber Cancer Institute (22) · University of Chicago (14) · University of Washington (13) · Abramson Cancer Center at Penn Medicine (12)

Often tested with

Tested in the same studies.

Lenvatinib (97) · Nivolumab (40) · Olaparib (38) · Paclitaxel (38) · Carboplatin (33) · Enfortumab vedotin (24) · Cisplatin (22) · Ipilimumab (18)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 69 phase 3 studies under way

Pembrolizumab is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 144, 16 in phase 3

Studies that test pembrolizumab, phase 3 first.

Studies

Open first, then newest update. How each study uses pembrolizumab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 1,134

See all 1,134 studies that test pembrolizumab →

Behind its US label · 53 — the studies the FDA label of KEYTRUDA describes

From the Clinical Studies section of KEYTRUDA (2026-07), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 368 — no other medicine in its arm

Showing 20 of 368. See all 368 →

Tested with established drugs · 245 — they are given beside it

Showing 20 of 245. See all 245 →

Tested in a combination · 521 — another drug in the study is under test too

Showing 20 of 521. See all 521 →

Given beside what is tested · 1,547 — usual care or a partner of the new treatment

Showing 20 of 1,547. See all 1,547 →

As the comparator · 114 — what is tested is compared with pembrolizumab

Showing 20 of 114. See all 114 →

Observed · 171 — patients on it are followed, or it is given outside a trial

Showing 20 of 171. See all 171 →

As a tool · 13 — an imaging tracer or a test of drug response

What changed recently

From the registry's own updates since Oct 15, 2026.

Started recruiting2

Results posted5

Stopped3

Newly registered3

Codes

What other systems call pembrolizumab · ClinicalTrials.gg INT006316

  • MeSH (NLM) C582435pembrolizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) DPT0O3T46PPEMBROLIZUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 1547545Confirmed FDA, Wikidata
  • Wikidata Q13896859pembrolizumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C106432PembrolizumabOne source FDA
  • DrugBank DB09037One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion